Brief: Oxigene announces $10 mln at-the-market registered direct offering
20/03/2015 12:00
March 20 (Reuters) - OXiGENE Inc OXGN.O : * Announces $10 million at-the-market registered direct offering * Entered into definitive agreements to purchase $10 million of registered shares of Oxigene common stock at $1.7125 per share * Intends to use proceeds from offering to advance the clinical development of its lead clinical product candidate, fosbretabulin * Source text for Eikon ID:nGNXVDBVPa * Further company coverage OXGN.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas